# Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

> **NCT05438498** · PHASE3 · TERMINATED · sponsor: **MediMergent, LLC** · enrollment: 550 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **DRUG:** Evusheld (tixagevimab+cilgavimab) IM or IV

## Key facts

- **NCT ID:** NCT05438498
- **Lead sponsor:** MediMergent, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-03
- **Primary completion:** 2023-04-29
- **Final completion:** 2023-06-30
- **Target enrollment:** 550 (ACTUAL)
- **Why stopped:** FDA withdrew EUA for AZD7442
- **Last updated:** 2023-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05438498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05438498, "Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05438498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*